Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1642-1648

  Lim, Seng Gee ^a   Krastev, Zahary ^b   Ng, Tay Meng ^c   Mechkov, Grigor ^d   Kotzev, Iskren Andreev ^e   Chan, Sing ^f   Mondou, Elsa ^g   Snow, Andrea ^g   Sorbel, Jeff ^g   Rousseau, Franck ^g  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^c CHANGI GENERAL HOSPITAL   (Singapore)

^d Vth Polyprofile Hospital for Active Treatment   (Bulgaria)

^e MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CLEVUDINE; DIURETIC AGENT; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; ASCITES; ASIAN; ASSAY; BLOOD CLOTTING DISORDER; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GONOCOCCAL ARTHRITIS; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERGLYCEMIA; INFLUENZA; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEX RATIO; SORE THROAT; THORAX PAIN; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VERTEBRA FRACTURE; VIREMIA; VIRUS LOAD; VIRUS MUTATION;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; AMYLASES; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; ASPARTATE AMINOTRANSFERASES; BICARBONATES; BILIRUBIN; BLOOD GLUCOSE; CREATINE KINASE; DEOXYCYTIDINE; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROLYTES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SERUM ALBUMIN;

EID: 33646438502     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1642-1648.2006     Document Type: Article

References (29)

1. AIDS Clinical Trial Group. 1996. Division of AIDS table for grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Md.
2. Applied Biosystems. 2003. ABI Prism 3100 genetic analyzers users guide. Applied Biosystems, Foster City, Calif.
3. Chappell, B., M. Curtis, A. Snow, Y. Zhu, C. Wakeford, and J. Harris. 2004. A comparative analysis of two hepatitis B virus (HBV) viral load assays: real-time PCR versus hybrid capture, poster abstract 47. Presented at the 17th International Conference on Antiviral Research, Tucson, Ariz., May 2004.
4. Chu, C. K., T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S. B. Pai, G. Q. Yao, J. P. Sommadossi, and Y. C. Cheng. 1995. Use of 2′-fluoro-methyl- β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39:979-981.
5. Cooksley, W. G. 2004. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin. Liver Dis. 24:45-53.
6. Craxi, A., D. Di Bona, and C. Camma. 2003. Interferon alpha for HBeAg positive chronic hepatitis B: systematic review. J. Hepatol. 39(Suppl. 1):99-105.
7. Curtis, M., Y. Zhu, and M. Jackson. 2004. Highly sensitive and accurate real-time PCR assay for hepatitis B viral load quantification, poster abstract 48. Presented at the 17th International Conference on Antiviral Research, Tucson, Ariz., May 2004.
8. Dienstag, J. L., E. R. Schiff, T. L. Wright, R. P. Perrillo, H.-W. Kann, Z. Goodman, L. Crowther, L. D. Condreay, M. Woessner, M. Rubin, and N. A. Brown. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
9. Gish, R. G., N. W. Y. Leung, T. L. Wright, H. Trinh, W. Lang, H. A. Kessler, L. Fang, L. H. Wang, J. Delehanty, A. Rigney, E. Mondou, A. Snow, and F. Rousseau. 2002. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimierob. Agents Chemother. 46:1734-1740.
10. Gish, R. G., H. Trinh, N. Leung, F. K. L. Chan, M. W. Fried, T. L. Wright, C. Wang, J. Anderson, E. Mondou, A. Snow, J. Sorbel, F. Rousseau, and L. Corey. 2005. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection. A two-year study. J. Hepatol. 43:60-66.
11. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T.-T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
12. Jacquard, A. C., M. Nassal, C. Pichoud, S. Ren, U. Schultz, S. Guerret, M. Chevallier, B. Werle, S. Peyrol, C. Jamard, L. T. Rimsky, C. Trepo, and F. Zoulim. 2004. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 48:2683-2692.
13. Keeffe, E. B., D. T. Dieterich, S.-H. B. Han, I. M. Jacobson, P. Martin, E. R. Schiff, H. Tobias, and T. L. Wright. 2004. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol. Hepatol. 2:87-106.
14. Korba, B. E. 1996. In vitro evaluation of combination therapies against hepatitis B virus replication. Antivir. Res. 29:49-51.
15. Korba, B. E., C. K. Chu, E. Hill, and P. Furman. 1999. Effectiveness of combination therapies against hepatitis B virus (HBV) replication in vitro, poster abstract 56. Presented at the 12th International Conference on Antiviral Research, Jerusalem, Israel, March 1999.
16. Kumar, R., and B. Agrawal. 2004. Novel treatment options for hepatitis B virus infection. Curr. Opin. Investig. Drugs 5:171-178.
17. Ladner, S. K., T. J. Miller, and R. W. King. 1998. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42:2128-2131.
18. Ladner, S. K., M. J. Otto, C. S. Barker, K. Zaifert, G. H. Wang, J. T. Guo, C. Seeger, and R. W. King. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
19. Lai, C.-L., R.-N. Chien, N. W. Y. Leung, T.-T. Chang, R. Guan, D.-I. Tai, K.-Y. Ng, P.-C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and D. F. Gray. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
20. Lok, A. S., E. J. Heathcote, and J. H. Hoofnagle. 2001. Management of hepatitis B 2000-summary of a workshop. Gastroenterology 120:1828-1853.
21. Mantel, N. 1963. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. Am. Stat. Assoc. J. 58:690-700.
22. Marcellin, P., T.-T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
23. Marcellin, P., G. K. K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z.-M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, M. Diago, S. Gurel, M-Y. Lai, P. Button, and N. Pluck. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351:1206-1217.
24. Marcellin, P., N. Leung, H.-W. L. Hann, G. K. K. Lau, C. Trepo, S. Sacks, H. Mommeja-Marin, C. Moxham, A. Snow, F. Rousseau, and S. G. Lim. 2004. A phase II, randomized trial evaluating the safety, pharmacokinetics and antiviral activity of clevudine for 12 weeks in patients with chronic hepatitis B, poster abstract 1129. Presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Mass., November 2004.
25. Marcellin, P., H. Mommeja-Marin, S. L. Sacks, G. K. K. Lau, D. Sereni, J.-P. Bronowicki, B. Conway, C. Trepo, M. R. Blum, B. C. Yoo, E. Mondou, J. Sorbel, A. Snow, F. Rousseau, and H.-S. Lee. 2004. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40:140-148.
26. Peek, S. F., P. J. Cote, J. R. Jacob, I. A. Toshkov, W. E. Hornbuckle, B. H. Baldwin, F. V. Wells, C. K. Chu, J. L. Gerin, B. C. Tennant, and B. E. Korba. 2001. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl- β-L-arabinofuranosyl)uracil)] against woodchuck hepatitis virus and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33:254-266.
27. Seigneres, B., C. Pichoud, P. Martin, P. Furman, C. Trepo, and F. Zoulim. 2002. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36:710-722.
28. van Elteren, P. H. 1958. On the combination of independent two sample tests of Wilcoxon. Bull. Int. Stat. Inst. 37:351-361.
29. Zhu, Y., T. Yamamoto, J. Cullen, J. Saputelli, C. E. Aldrich, D. S. Miller, S. Litwin, P. A. Furman, A. R. Jilbert, and W. S. Mason. 2001. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75:311-322.